

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

**LasR regulates protease IV expression at suboptimal growth temperatures in  
*Pseudomonas aeruginosa***

Running title: LasR regulates protease IV expression

Rachel E. Done<sup>a,b</sup>, Joshua K. Robertson<sup>c</sup>, Samantha M. Prezioso<sup>a,b\*</sup>, and Joanna B. Goldberg<sup>b,d#</sup>

<sup>a</sup>Microbiology and Molecular Genetics Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, Georgia, USA

<sup>b</sup>Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA

<sup>c</sup>Department of Biology, Emory University, Atlanta, Georgia, USA

<sup>d</sup>Emory+Children's Center for Cystic Fibrosis and Airway Disease Research, Emory University School of Medicine, Atlanta, Georgia, USA

\*Present address: Alltrna, Boston, Massachusetts, USA

Abstract word count: 238 words

Importance word count: 134 words

Manuscript text word count: 4,941 words

# Address correspondence to Joanna B. Goldberg, [joanna.goldberg@emory.edu](mailto:joanna.goldberg@emory.edu).

## 20 **ABSTRACT**

21 The opportunistic pathogen *Pseudomonas aeruginosa* causes debilitating lung infections in  
22 people with cystic fibrosis, as well as eye, burn, and wound infections in otherwise  
23 immunocompetent individuals. Many of *P. aeruginosa*'s virulence factors are regulated by  
24 environmental changes associated with human infection, such as a change in temperature from  
25 ambient to human body temperature. One such virulence factor is protease IV (PIV).  
26 Interestingly, *piv* expression is higher at ambient temperatures (22-28°C) compared to human  
27 body temperature (37°C). We found that *piv* expression was thermoregulated at stationary  
28 phase, but not exponential phase, and that *piv* is thermoregulated at the level of transcription.  
29 Protein levels of known transcriptional regulators of *piv*, the quorum sensing regulator LasR and  
30 the gene-silencing histone nucleoid silencing proteins MvaT/MvaU, were not thermoregulated.  
31 Using a transcriptional reporter for *piv*, we show that LasR activates *piv* expression at stationary  
32 phase at 25°C but not 37°C, while MvaT/MvaU are not required for *piv* thermoregulation. We  
33 also identified a *las* box in the *piv* promoter, which is important for *piv* thermoregulation. We  
34 propose that LasR directly regulates *piv* at stationary phase at 25°C but has a negligible impact  
35 at 37°C. Here, we show that *piv* is uniquely regulated by LasR in a temperature-dependent  
36 manner. Our findings suggest that the LasRI quorum sensing regulon of *P. aeruginosa* may not  
37 be fully characterized and that growth at non-standard laboratory conditions such as lower  
38 temperatures could reveal previously unrecognized quorum sensing regulated genes.

39

## 40 **IMPORTANCE**

41 *Pseudomonas aeruginosa* is a versatile opportunistic pathogen capable of causing many  
42 different types of infections that are often difficult to treat, such as lung infections in people with  
43 cystic fibrosis. Temperature regulates the expression of many virulence factors that contribute to  
44 *P. aeruginosa*'s ability to cause infection, yet our mechanistic understanding of virulence factor

45 thermoregulation is poor. In this study, we show that the virulence factor protease IV is  
46 thermoregulated at the level of transcription via temperature-dependent upregulation by the  
47 quorum sensing regulator, LasR. Mechanistic studies of virulence factor thermoregulation will  
48 expand our understanding of how *P. aeruginosa* experiences different environments, including  
49 the mammalian host. Our work also highlights the importance of growth conditions in studying  
50 gene regulation, as it elucidates the regulation of protease IV by LasR, which was previously not  
51 well understood.  
52

## 53 INTRODUCTION

54 *Pseudomonas aeruginosa* is a highly adaptable bacterial pathogen that causes lung, burn,  
55 wound, and corneal infections. To survive in the diverse niches of the human body, *P.*  
56 *aeruginosa* adapts to its environment and regulates the expression of many virulence factors  
57 that assist in nutrient acquisition and immune evasion. A major environmental cue that regulates  
58 virulence in many pathogenic bacteria, including *P. aeruginosa*, is the change in temperature  
59 from ambient or room temperature to that encountered in or on the human body (1, 2). Human  
60 body temperature is generally accepted to be 37°C but can be lower at body sites exposed to  
61 the environment, such as the skin and eyes.

62 Many virulence factors in *P. aeruginosa* are regulated by temperature and mechanisms  
63 of thermoregulation have been studied at the post-transcriptional (2) and post-translational  
64 levels (3–5). Thermoregulation at the level of transcription has not been as extensively studied,  
65 despite the finding that expression of 6.4% of the genome is regulated by temperature, with  
66 many virulence factors upregulated at 37°C compared to ambient temperatures (6, 7).  
67 Interestingly, expression of the gene encoding the virulence factor protease IV (PIV) is greatly  
68 upregulated at ambient temperatures compared to 37°C in both of the laboratory strains PAO1  
69 and PA14 (6, 7). PIV is a serine protease that degrades a broad range of immune molecules,  
70 including the iron sequestering lactoferrin and transferrin, complement C3 found in blood, as  
71 well as alveolar surfactant proteins and IL-22 that provide protection in the lungs (8–11). PIV  
72 has been extensively characterized as a key virulence factor for *P. aeruginosa* eye infections  
73 and strains lacking PIV are rendered avirulent in corneal infections (12–15). Corneal infections  
74 can be difficult to treat with severe patient outcomes, as seen in a recent carbapenem-resistant  
75 *P. aeruginosa* outbreak caused by contaminated artificial tears that resulted in multiple deaths,  
76 instances of moderate to complete loss of vision, and enucleation due to the infection (16).

77 PIV is initially translated as a ~48 kD pre-proenzyme that contains an N-terminal signal  
78 sequence, an inactivating propeptide, and the protease domain (17). The signal sequence is  
79 cleaved during secretion and the remaining propeptide renders the 45 kD proenzyme  
80 catalytically inactive; release of the propeptide is required to yield the 26 kD, enzymatically  
81 active (“mature”), protease. Cleavage of the propeptide has been reported to occur  
82 autocatalytically and by the *P. aeruginosa* elastase LasB in bacterial supernatants (9, 18, 19).

83 Transcriptional regulation of *piv* is also complex and not fully understood. *piv* expression  
84 is directly upregulated by the sigma factor PvdS under iron starvation conditions, leading to the  
85 gene’s alternative name *prpL* (PvdS-regulated endoprotease, lysyl class) (20). *piv* expression is  
86 directly repressed by the histone nucleoid structuring (H-NS) family members MvaT and MvaU,  
87 which act together to negatively regulate the same global regulon (21, 22). *piv* is also regulated  
88 by the LasRI quorum sensing system (23–25). The LasRI quorum sensing system is a  
89 mechanism for *P. aeruginosa* to coordinate expression of certain genes at high cell densities  
90 through the autoinducer synthase LasI synthesizing the freely diffusible homoserine lactone  
91 (HSL) autoinducer 3-oxo-C12-HSL (3O-C12-HSL), which complexes with transcription factor  
92 LasR to activate its function as a positive regulator of hundreds of genes (23–26). LasR has not  
93 been found to directly bind to the *piv* promoter and the mechanism(s) by which it regulates *piv* is  
94 not clear (27). Additionally, how *piv* expression is regulated by temperature is not understood  
95 and is important for our understanding of how *P. aeruginosa* adapts to body sites which can  
96 experience lower temperatures due to exposure to the environment.

97 We found that *piv* thermoregulation occurs at the level of transcription due to significantly  
98 higher promoter activity at room temperature (25°C) compared to human body temperature  
99 (37°C). Higher *piv* expression at ambient temperatures was reflected in a higher level of mature  
100 PIV protein, suggesting that temperature regulation could affect the amount of this virulence  
101 factor produced by *P. aeruginosa* in infection sites experiencing different temperatures. Our

102 study outlines the role of LasR as an activator of *piv* expression at 25°C but not 37°C and  
103 provides evidence for direct LasR regulation of *piv*. This suggests that LasRI quorum sensing  
104 may regulate certain genes disparately under conditions different from those standardly used in  
105 the laboratory.

106

## 107 **RESULTS**

### 108 **Thermoregulation of *piv* depends on growth phase.**

109 A previous transcriptomic study from our group showed by microarray analysis that *piv* was  
110 more highly expressed at 22°C compared to 37°C in *P. aeruginosa* PAO1 (6). Similar results  
111 were found in an RNA-seq analysis of *P. aeruginosa* PA14 grown at 28°C compared to 37°C (7).  
112 However, both transcriptomes were determined for cells at stationary phase and only examined  
113 two temperatures: a “low” or ambient temperature and human body temperature, 37°C. We  
114 wanted to examine *piv* expression at additional temperatures to characterize if *piv*  
115 thermoregulation is binary with a ‘high’ and ‘low’ expression state or continuous with expression  
116 changing gradually as temperature changes. We also wanted to determine if growth phase  
117 affected *piv* thermoregulation. Wild-type *P. aeruginosa* PAO1 was grown in parallel at 25°C,  
118 30°C, 37°C, and 42°C and RNA extracted from cultures at each temperature, first at exponential  
119 phase and then from the same cultures at early stationary phase (Fig. 1A). *piv* expression at  
120 each temperature was determined relative to 37°C (a standard laboratory condition) at each  
121 growth phase using RT-qPCR. Interestingly, we found that *piv* thermoregulation depended on  
122 growth phase. At exponential phase, *piv* expression was not regulated by temperature (Fig. 1B).  
123 However, at stationary phase, *piv* expression at 25°C and 30°C was ~16-fold and ~10-fold  
124 higher, respectively, than at 37°C and ~6-fold lower at 42°C than 37°C. These results support  
125 *piv* thermoregulation as continuous within the range of tested temperatures, with highest

126 expression observed at 25°C and expression decreasing gradually as temperature increases to  
127 42°C.

128 We then determined whether *piv* transcript levels were reflected in levels of PIV protein  
129 in cells grown at different temperatures. To test this, we used PAO1 PIV VSV-G, in which the  
130 native *piv* locus was tagged at the C-terminus with the vesicular stomatitis virus G (VSV-G)  
131 epitope. The C-terminal placement of the VSV-G tag would allow for detecting the 48 kD pre-  
132 proenzyme, the 45 kD proenzyme, and the 26 kD mature enzymatic forms of PIV, as processing  
133 of the full-length gene product involves proteolysis from the N-terminus (9, 17). PAO1 PIV VSV-  
134 G was grown at 25°C, 30°C, 37°C, and 42°C to early stationary phase and cell lysates were  
135 subjected to quantitative western blotting with VSV-G antibodies ( $\alpha$ VSV-G) as well as with RNA  
136 polymerase  $\alpha$  subunit antibodies ( $\alpha$ RpoA) as a temperature independent control (Fig 2A,B). We  
137 found that the abundance of the 26 kD mature PIV VSV-G domain was significantly higher at  
138 25°C and 30°C than at 37°C. Mature PIV VSV-G was hardly detected at 42°C. An unprocessed  
139 form of PIV could be detected at approximately 50 kD at 25°C and 30°C but not at 37°C or  
140 42°C; however, we were not able to distinguish between the 48 kD pre-proenzyme and 45 kD  
141 proenzyme forms of PIV. The abundance of mature PIV VSV-G at each temperature agrees well  
142 with *piv* expression data, suggesting there is likely not temperature-dependent post-  
143 transcriptional modification of *piv*. Together, these results show that *piv* thermoregulation  
144 depends on growth phase and thermoregulation of *piv* gene expression is reflected in the  
145 abundance of PIV protein.

#### 146 **Transcriptional regulators of *piv* are not thermoregulated.**

147 Previous studies have shown that LasRI quorum sensing positively regulates *piv* (23–25) and  
148 the H-NS family members MvaT and MvaU directly repress *piv* expression (21, 22). One  
149 possible mechanism for the thermoregulation of *piv* expression could be thermoregulation of  
150 transcriptional regulators of *piv*. We asked if the quorum sensing regulator LasR was more

151 abundant at 25°C than 37°C, and/or if the repressors MvaT and MvaU were more abundant at  
152 37°C than 25°C, as a possible mechanism for *piv* thermoregulation. We first examined gene  
153 expression of *lasR*, *mvaT*, and *mvaU* in PAO1 grown at 25°C and 37°C at both exponential and  
154 stationary phases (Fig. 3A). The expression of each transcriptional regulator was not  
155 significantly regulated by temperature, even at stationary phase, when *piv* is most  
156 thermoregulated. This suggested that LasR, MvaT, and MvaU are not themselves  
157 thermoregulated, which is consistent with other studies that did not identify these genes as  
158 thermoregulated (6, 7). To confirm that the protein abundance of LasR, MvaT, and MvaU was  
159 not regulated by temperature, we assessed the level of each protein in cells grown at 25°C and  
160 37°C to stationary phase by quantitative western blotting. Blotting in PAO1 with antibodies  
161 raised to LasR in rabbits (25) confirmed that the level of LasR protein was not significantly  
162 different at 25°C compared 37°C (Fig. 3B). Blotting with  $\alpha$ VSV-G antibodies in the PAO1 MvaT  
163 VSV-G (Fig. 3C) and PAO1 MvaU VSV-G strains (Fig. 3D) with C-terminal VSV-G epitope  
164 tagged *mvaT* and *mvaU* at the native loci also showed that levels of MvaT VSV-G and MvaU  
165 VSV-G were also not significantly different at 25°C compared to 37°C. These results indicate  
166 that transcriptional regulators LasR, MvaT, and MvaU are not themselves thermoregulated.

167 ***piv* expression is regulated by temperature at the level of transcription.**

168 Another possible mechanism for the thermoregulation of *piv* expression could be temperature  
169 dependent *piv* promoter activity. To test this, we made a transcriptional reporter by fusing the  
170 200 bp upstream of the *piv* coding sequence to an unstable green fluorescent protein variant,  
171 *gfp*(ASV) (28) that has been previously used for transcriptional reporters (29). PAO1 carrying  
172 the  $P_{piv}$ -*gfp*(ASV) reporter plasmid (pRD91) was grown at 25°C and 37°C and assayed for  
173 fluorescence at exponential phase (Fig. 4A) and then again at stationary phase (Fig. 4B). PAO1  
174 carrying a no-promoter *gfp*(ASV) reporter plasmid (pRD87) was used to assess background  
175 fluorescence, which was overall low at both temperatures and growth phases (Fig. S1). At both

176 exponential and stationary phases, *piv* promoter activity in PAO1 was higher at 25°C than 37°C,  
177 with promoter activity at 37°C not above the background (Fig. 4A,B). Promoter activity at 25°C  
178 was also higher at stationary phase than exponential phase. The finding that promoter activity  
179 was thermoregulated and affected by growth phase suggests that the growth phase dependent  
180 thermoregulation of *piv* observed in Fig. 1 is due to differences in *piv* promoter activity.

181 Although the abundance of transcriptional regulators LasR, MvaT, and MvaU was not  
182 thermoregulated, we wondered if their regulation of *piv* was affected by temperature since the  
183 *piv* promoter is sufficient to drive thermoregulation. To test if LasR was required for *piv*  
184 thermoregulation, we assayed a  $\Delta lasR$  mutant carrying the  $P_{piv}$ -*gfp*(ASV) reporter for  
185 fluorescence at 25°C and 37°C as described; there was no promoter activity above background  
186 levels at either 25°C or 37°C, at both exponential and stationary phases (Fig. 4A, B). Expressing  
187 LasR in single copy from the ectopic Tn7 site complemented the  $\Delta lasR$  mutation, restoring wild-  
188 type *piv* promoter thermoregulation. This shows that LasR is required for *piv* promoter activity at  
189 both 25°C and 37°C. To further confirm that *piv* was regulated by LasRI quorum sensing, we  
190 deleted the gene encoding the LasI autoinducer synthase and assayed the  $\Delta lasI$  mutant for  
191 activity from the *piv* transcriptional reporter (Fig. 4A,B). Promoter activity in the  $\Delta lasI$  mutant  
192 phenocopied that of the  $\Delta lasR$  mutant, supporting *piv* being regulated by LasRI quorum sensing.

193 In the  $\Delta mvaT\Delta mvaU$  mutant, promoter activity at exponential phase was overall higher  
194 at both temperatures than in PAO1 and was slightly thermoregulated; however, at stationary  
195 phase promoter activity was highly thermoregulated (Fig. 4). Expressing either MvaT or MvaU in  
196 single copy from the ectopic Tn7 site complemented the  $\Delta mvaT\Delta mvaU$  mutation. Since  
197 promoter activity is thermoregulated at stationary phase in the  $\Delta mvaT\Delta mvaU$  mutant, this result  
198 indicates that MvaT and MvaU are not required for *piv* thermoregulation. To test if LasR was  
199 responsible for thermoregulation in the  $\Delta mvaT\Delta mvaU$  mutant and to assess the role of LasR in  
200 *piv* thermoregulation in the absence of strong repressors MvaT and MvaU, we deleted *lasR*

201 from the  $\Delta mvaT\Delta mvaU$  strain. At exponential phase, promoter activity in  $\Delta mvaT\Delta mvaU\Delta lasR$   
202 was overall derepressed and slightly thermoregulated, phenocopying  $\Delta mvaT\Delta mvaU$  (Fig. 4A,B).  
203 However, at stationary phase, promoter activity in  $\Delta mvaT\Delta mvaU\Delta lasR$  was significantly less  
204 thermoregulated due to a decrease in *piv* promoter activity at 25°C with no change at 37°C.  
205 Thus, deleting *lasR* from  $\Delta mvaT\Delta mvaU$  revealed that LasR only increases promoter activity at  
206 stationary phase at 25°C and that LasR does not seem to regulate *piv* at 37°C.

207 Collectively, these results reveal that *piv* thermoregulation is occurring due to  
208 temperature dependent promoter activity which requires the transcriptional regulator LasR but  
209 not MvaT nor MvaU.

#### 210 **LasR directly regulates *piv*.**

211 To determine how *piv* expression was being thermoregulated by LasR, we first analyzed the *piv*  
212 promoter region more closely. We had found that 200 nucleotides upstream of the *piv* coding  
213 region (Fig. 5A) was sufficient for thermoregulation of its promoter activity. The *piv* upstream  
214 region was recently identified as containing a  $\sigma^{70}$ -dependent promoter (22). Using SAPPHIRE  
215 (30), a predictor for  $\sigma^{70}$  promoters in *Pseudomonas* spp., we identified the putative -35 and -10  
216 elements for the sigma factor RpoD (Fig. 5A, underlined regions). Putative transcription start  
217 sites (TSSs) for *piv* were mapped using 5' rapid amplification of cDNA ends (5' RACE) in PAO1  
218 (Fig. 5A, highlighted bases). We found that transcription began at positions 151C or 152G of the  
219 promoter region sequence. The predicted -35 and -10 elements are appropriately positioned  
220 upstream of our TSSs such that RpoD could be directing transcription of *piv* beginning at 151C  
221 or 152G of the promoter.

222 We then analyzed the region upstream of the TSSs and predicted  $\sigma^{70}$  -35 and -10  
223 elements and identified a 16 bp sequence (Fig. 5A, boxed region) that resembles a canonical  
224 *las* box, particularly the one identified for non-cooperative LasR binding (27). We hypothesized  
225 that LasR could be directly regulating *piv* by binding to this region. To test this, we introduced

226 point mutations to the putative *las* box in the  $P_{piv}$ -*gfp*(ASV) reporter plasmid (pRD91) at highly  
227 conserved positions that we predict would either disrupt (Fig. 5B, pink base changes) or  
228 improve (Fig. 5B, green base changes) potential LasR binding. The predicted deleterious  
229 mutations were among ones that have been previously shown to abolish LasR binding to and  
230 greatly reduce activity of the *pqsR* promoter (31, 32). We then assayed the effects of these  
231 mutations on *piv* promoter activity at 25°C and 37°C in PAO1 (Fig. 5C). The predicted  
232 deleterious 1C→A and 14T→A mutations of the putative *las* box reduced *piv* promoter activity  
233 slightly at exponential phase and greatly at stationary phase at 25°C only. Since these  
234 mutations greatly reduced the effect of growth phase on *piv* promoter activity only at 25°C,  
235 these results are consistent with the role of LasR as a quorum sensing regulator that is more  
236 active at stationary phase. The 16T→G mutation, predicted to improve LasR binding, increased  
237 promoter activity at both 25°C and 37°C; however, promoter activity was still highly  
238 thermoregulated. These results are consistent with our prediction for the location of a *las* box in  
239 the *piv* promoter.

240

## 241 **DISCUSSION**

242 Here, we found that *piv* thermoregulation occurs at the level of transcriptional regulation and  
243 requires the quorum sensing regulator LasR but not the H-NS family members MvaT/MvaU. By  
244 leveraging a  $\Delta mvaT\Delta mvaU$  mutant strain in which *piv* expression was depressed, we show that  
245 LasR acts as a positive regulator of *piv* at 25°C with little to no effect on *piv* expression at 37°C.  
246 This is consistent with our findings that *piv* expression is significantly thermoregulated at  
247 stationary phase but not at exponential phase, as LasR abundance and activity is higher at  
248 stationary phase (25). We also identify a putative *las* box in the *piv* promoter and provide  
249 evidence that LasR directly regulates *piv*.

250 **The role of *piv* and its thermoregulation in *P. aeruginosa* virulence**

251 Thermoregulation of *piv* may underpin the importance of this protease for infections of surface  
252 exposed body sites, such as the eyes or skin. Corneal infections by *P. aeruginosa* can lead to  
253 permanent loss of vision and death as seen in a recent outbreak caused by contamination of  
254 artificial tear drops (16). PIV causes epithelial erosion in the cornea and contributes to bacterial  
255 virulence, and *P. aeruginosa* lacking PIV is practically avirulent in corneal models of infection  
256 (12–15). PIV also severely impaired wound healing and contributed to elevated levels of  
257 inflammation in a wound model of infection in mice (33, 34). At temperatures lower than 37°C,  
258 which could be experienced by the bacteria in surface exposed infections, many virulence  
259 factors such as LasB and type III secretion are downregulated, while PIV is upregulated (6, 7).  
260 The unique thermoregulation of PIV may in part contribute to the severity of corneal infections  
261 and to the success of *P. aeruginosa* as an ocular pathogen, as well as the ability of *P.*  
262 *aeruginosa* to cause chronic infections of wounds.

### 263 **Thermoregulation of *piv* has impacted its study.**

264 Many studies of PIV processing, secretion, and post-secretion activation have utilized *in vitro*  
265 experiments or expressed PIV in heterologous hosts, which has led to some inconsistencies in  
266 the model for PIV post-secretion activation. One study in PAO1 showed that the propeptide  
267 could only be degraded by protease LasB in *in vitro* assays (although the ability of PIV to  
268 degrade its own propeptide was not tested) and proposed that the PIV proenzyme is secreted  
269 into supernatant and then processed into the mature form by LasB (18). However, earlier  
270 studies found that PIV purified from the supernatant of PA103-29, a derivative of PA103 that  
271 lacks LasB, was enzymatically active, as was PIV when expressed in *Pseudomonas putida* and  
272 *Escherichia coli* (14, 17, 35). In both heterologous hosts, mature PIV was found in cell  
273 supernatants, indicating that LasB is not required for the removal of the propeptide from the  
274 proenzyme and suggesting that this maturation step may occur autocatalytically. Mutants of PIV  
275 that lacked catalytic activity could not be processed from the proenzyme into the mature  
276 protease, further supporting an autocatalytic cleavage mechanism of the propeptide (9). We

277 found significant amounts of mature PIV inside cells of PAO1 at 25°C and 30°C (Fig. 2), as well  
278 as low levels of precursor forms, which supports a path for the maturation of PIV inside cells  
279 and not just in the supernatant. As LasB is inactive in the cytoplasm of *P. aeruginosa*, we  
280 believe our results show that PIV can mature autocatalytically in PAO1.

281 Prior studies on the secretion and protease activity of PIV have been hampered due to  
282 the low amount of PIV produced from the native chromosomal locus (8, 17). We postulate that  
283 the low level of PIV observed by others was due to thermoregulation of *piv* expression, as the  
284 studies were all conducted at 37°C. Consistent with this, we detected abundant PIV in both  
285 mature and precursor(s) forms at 25°C and 30°C but very little mature and no precursor PIV at  
286 37°C or higher (Fig. 2). Our findings demonstrate that PIV produced from its native locus can be  
287 easily detected in cells grown at 25°C and propose this as a viable alternative to yield high *piv*  
288 expression and/or high PIV protein levels for further studies of PIV secretion and maturation.

### 289 **A model for thermoregulation of *piv* by LasR**

290 We propose a model for *piv* thermoregulation in which LasR activates *piv* transcription at  
291 stationary phase by interacting with a newly identified *las* box in the *piv* promoter at 25°C but not  
292 at all, or very lowly, at 37°C and higher (Fig. 6). In wild-type cells growing at 25°C, LasR  
293 increases *piv* promoter activity while MvaT and MvaU appear to have no regulatory effect. Given  
294 that the loss of *lasR* results in no detectable promoter activity at 25°C and that further deletion of  
295 *mvaT* and *mvaU* from  $\Delta$ *lasR* restores promoter activity (Fig. 4), we suspect that MvaT/MvaU do  
296 not repress at 25°C due to LasR interfering with MvaT/MvaU interacting with the *piv* promoter. In  
297 a wild-type cell growing at 37°C, *piv* promoter activity is barely detectable and LasR appears to  
298 have no regulatory effect on *piv* (Fig. 4). MvaT/MvaU repress *piv* at 37°C, which we suggest is  
299 due to the lack of LasR interference at the promoter. And while PvdS is a known regulator of *piv*  
300 in low iron conditions, since our experiments were all conducted in iron replete LB media in  
301 which PvdS is inactive, *piv* thermoregulation must not require PvdS.

302 It remains unclear how temperature is modulating LasR regulation of *piv*. In agreement with  
303 prior studies (36), we determined that LasR expression and protein levels are not temperature  
304 dependent (Fig. 3) and thus the amount of LasR is not driving higher *piv* expression at lower  
305 temperatures. Additionally, although translation of LasI is slightly higher at 37°C than 30°C due  
306 to an RNA thermometer, this has been shown to only result in a small increase of 3O-C12-HSL  
307 levels that had no effect on expression of the LasR-regulated *lasB* or the amount of the gene  
308 product elastase (36). Given this and that *piv* expression is higher at ambient temperatures of  
309 25°C-30°C than 37°C (the opposite of how LasI is thermoregulated), we do not believe that the  
310 general activity of the LasRI quorum system itself is thermoregulated nor responsible for  
311 thermoregulating *piv*. A second quorum sensing system in *P. aeruginosa*, the RhlRI system, is  
312 thermoregulated due to an RNA thermometer that results in higher RhlR levels at 37°C. The  
313 thermoregulation of the transcriptional activator RhlR does result in higher levels of RhlR-  
314 regulated virulence factors, like rhamnolipids, at 37°C (36); however, *piv* is not regulated by the  
315 RhlRI quorum sensing system, and furthermore is upregulated at temperatures lower than 37°C,  
316 indicating that RhlRI is not responsible for *piv* thermoregulation (25).

317 We postulate that thermoregulation of *piv* by LasR involves an interaction between LasR  
318 and specifically the *piv* promoter that is temperature sensitive. Lower temperatures such as  
319 25°C may favor LasR interacting with the *piv* promoter at the identified *las* box to mediate *piv*  
320 thermoregulation. A previous study that identified promoters directly bound by LasR in PAO1  
321 failed to identify the *piv* promoter as one, despite identifying several known and novel LasR  
322 targets (27). In retrospect, this was likely because the experiment in this previous study was  
323 conducted at 37°C (27), a temperature at which our findings show that LasR does not regulate  
324 *piv*. We find a mutation designed to ‘improve’ the *las* box sequence within the *piv* promoter  
325 increases promoter activity at 37°C to detectable, albeit still low, levels (Fig. 5). This further  
326 supports that LasR directly regulates *piv*, but only under certain temperature conditions, which

327 could explain why prior experiments conducted at 37°C failed to identify *piv* as a directly LasR-  
328 regulated gene. To the best of our knowledge, this is the only gene known to be directly  
329 regulated by LasR in a temperature-dependent manner.

330 It is interesting that mutating the *las* box sequence toward consensus at highly conserved  
331 positions did not result in equal promoter activity at 25°C and 37°C (Fig 5). Thermoregulation of  
332 *piv* by LasR must not be solely due to the sequence of the *las* box. It is notable that the position  
333 of the *las* box is farther upstream of the *piv* TSSs we identified compared to the position of the  
334 *las* box in some other LasR bound promoters (7). The *piv* promoter is also unusually AT rich at  
335 ~59% compared to the *P. aeruginosa* PAO1 genomic average of ~33%. Genomic DNA that is  
336 high in AT content is more flexible and has been documented to adopt temperature sensitive  
337 secondary structures as “DNA thermometers” that can mediate temperature-dependent  
338 transcription factor binding and subsequent gene expression (1). The position of the putative *las*  
339 box within the *piv* promoter could be accessible to LasR at 25°C, but not 37°C, due to  
340 temperature-dependent structural changes of the promoter itself.

341 As previously discussed, LasR regulated genes have been extensively studied as part of the  
342 quorum sensing regulon in *P. aeruginosa* (23–25, 37). However, *piv* had not been identified as  
343 directly regulated by LasR prior to this study, likely due to low or nonexistent direct LasR  
344 regulation of *piv* under the standard laboratory growth temperature of 37°C. This raises the  
345 possibility that LasR activates transcription of other unknown genes only at specific conditions,  
346 included but not limited to non-optimal growth temperatures. Studying gene expression under  
347 non-standard laboratory conditions that mimic various other infection environments may expand  
348 our understanding of virulence factor regulation and quorum sensing in the diverse  
349 environments that *P. aeruginosa* can survive in.

350

351 **ACKNOWLEDGEMENTS**

352 We thank Drs. Simon Dove and Michael Gebhardt for providing key  $\Delta mvaT\Delta mvaU$  and parent  
353 PAO1 strains, as well as discussions regarding MvaT/MvaU and technical advice on quantitative  
354 immunoblotting. The  $\alpha$ LasR antibodies were kindly gifted by Drs. Ajai Dandekar and Pete  
355 Greenberg. We also thank the Goldbeg Lab for discussion and feedback on the manuscript.  
356 This work was supported by NIH grant EY028320 (to JBG). RED was supported by a NIH NRSA  
357 Pre-Doctoral Fellowship (F31 AI172335); RED and SMP were supported by the NIH funded  
358 Antimicrobial Resistance and Therapeutic Discovery Training Program at Emory University  
359 (AI106699). JKR was supported by the Emory Summer Undergraduate Research Experience  
360 (SURE) Program.

361

## 362 **MATERIALS AND METHODS**

### 363 **Bacterial strains and plasmids**

364 Bacterial strains, plasmids, and oligonucleotides are listed in the Supplemental Material, Tables  
365 S1-S3. Standard molecular biology practices were used to construct plasmids and all  
366 constructed plasmids were confirmed by sequencing. Mutant strains were confirmed by PCR  
367 and sequencing. Full plasmid and strain construction details are available in the Supplemental  
368 Material.

### 369 **Culture conditions**

370 Overnight cultures of *P. aeruginosa* were routinely grown in 3 mL of lysogeny broth (LB) at 37°C  
371 in a rolling drum. As appropriate, *E. coli* growth media was supplemented with gentamicin (15  
372  $\mu$ g/mL), carbenicillin (100  $\mu$ g/mL), or tetracycline (10  $\mu$ g/mL) and *P. aeruginosa* media with  
373 gentamicin (60  $\mu$ g/mL), carbenicillin (300  $\mu$ g/mL), or tetracycline (100  $\mu$ g/mL), unless otherwise  
374 noted.

### 375 **RNA extraction and DNase treatment**

376 To measure transcript levels at different growth temperatures, biological triplicates of PAO1  
377 grown overnight at 37°C were subcultured to an initial OD<sub>600</sub> of 0.05 in 25 mL LB and incubated  
378 shaking at 200 rpm at the indicated temperature. At exponential phase (OD<sub>600</sub> ~0.5), 10<sup>9</sup> cells  
379 were centrifuged and resuspended in 1 mL Tri-Reagent (Millipore Sigma) and RNA extracted  
380 according to the manufacturer's instructions, using chloroform. The cultures were allowed to  
381 continue growing until early stationary phase (OD<sub>600</sub> ~2.0) and RNA extracted again as  
382 described. 5 µg of extracted RNA was DNase treated with TURBO DNase (ThermoFisher)  
383 according to the manufacturer's instructions for rigorous DNase treatment.

#### 384 **Real time quantitative PCR (RT-qPCR)**

385 One-step RT-qPCR was performed on DNase treated RNA using Power SYBR™ Green RNA-  
386 to-CT™ 1-Step Kit (Applied Biosystems) on a LightCycler 96 (Roche) using LightCycler  
387 software v1.1.0.1320. Reactions were conducted in technical triplicate per each biological  
388 sample and the C<sub>q</sub> values were averaged for gene expression analysis using the temperature  
389 insensitive *omIA* (6) as an internal control gene. The relative expression of a gene at a given  
390 temperature X°C compared to 37°C was calculated and plotted as  $\log_2(2^{-\Delta\Delta Ct})$ , where  $\Delta\Delta Ct = (C_q$   
391  $\text{gene at } X^\circ\text{C} - C_q \text{ } omIA \text{ at } X^\circ\text{C}) - (C_q \text{ gene at } 37^\circ\text{C} - C_q \text{ } omIA \text{ at } 37^\circ\text{C})$ .

#### 392 **Immunoblotting**

393 Overnight biological triplicates were subcultured to an initial OD<sub>600</sub> of 0.05 in 25 mL LB and  
394 incubated shaking at 200 rpm at the indicated temperature. At early stationary (OD<sub>600</sub> ~2.0)  
395 phase, 0.5 mL was collected and resuspended in 475 µL Laemlli buffer with 25 µL β-  
396 mercaptoethanol and boiled for 15 minutes. 10 µL of prepared cell lysate sample was  
397 electrophoresed, transferred to a low-fluorescence PVDF membrane (Bio-Rad), and blocked for  
398 1 hour in Intercept Blocking Buffer (Li-Cor). Primary antibodies against the VSV-G epitope tag  
399 (Sigma, batch # 0000143676) were used at 1:5,000 overnight at 4°C and primary antibodies  
400 against LasR (25) used at 1:1,000 overnight at 4°C with fluorophore conjugated secondary

401 antibodies against rabbits used at 1:10,000 (Li-Cor, Lot No. D20803-09). Primary antibodies  
402 against the  $\alpha$ -subunit of RNA polymerase were used at 1:5,000 (BioLegend, Lot No. B376827)  
403 with fluorophore conjugated antibodies against mice (Li-Cor, Lot No. D20601-01) used at  
404 1:10,000. Membranes were imaged on a BioRad ChemiDoc Imager. Primary antibodies against  
405 LasR were validated by immunoblotting cell lysate from PAO1 and PAO1  $\Delta$ lasR (Fig. S2).  
406 Densitometry analysis was conducted on raw image files using ImageJ.

#### 407 **Transcriptional reporter assays**

408 Biological triplicates of strains with a transcriptional reporter plasmid were grown overnight at  
409 37°C and subcultured to an initial OD<sub>600</sub> of 0.1 in 25 mL LB supplemented with gentamicin 30  
410  $\mu$ g/mL and incubated shaking at 200 rpm at each 25°C and 37°C. At exponential phase (OD<sub>600</sub>  
411  $\sim$ 0.5), 10<sup>9</sup> cells were centrifuged at 10,000 rpm for 2 minutes, supernatant removed, and the  
412 pellet resuspended in 1 mL PBS. 200  $\mu$ L of each sample was then added to a black sided 96  
413 well plate in technical triplicate and the fluorescence measured (excitation 485 nm, emission  
414 515 nm) on a Synergy H1 plate reader (BioTek). At stationary phase (OD<sub>600</sub>  $\sim$ 2.0), 10<sup>9</sup> cells were  
415 sampled from the same cultures and fluorescence measured as described. The RFU of 200  $\mu$ L  
416 PBS on each plate was subtracted from technical replicates, which were then averaged per  
417 biological replicate. Background was determined by averaging all values from a transcriptional  
418 reporter assay of PAO1 carrying pRD87, a no-promoter control of the reporter plasmid.

#### 419 **5' rapid amplification of cDNA ends (5' RACE)**

420 PAO1 was grown at 25°C in LB to late log phase (OD<sub>600</sub>  $\sim$ 0.8), RNA extracted using MasterPure  
421 RNA Purification Kit (Epicentre), and treated with TURBO DNase as described. 5' RACE was  
422 conducted using the 5' RACE System for Rapid Amplification of cDNA Ends (ThermoFisher)  
423 according to manufacturer's instructions with modifications: ThermoScript Reverse  
424 Transcriptase (Invitrogen) was used in place of the kit's reverse transcriptase with betaine  
425 added to 0.5 M for the reverse transcriptase step.

426 **Statistical analyses**

427 All statistical tests were conducted as described using Prism version 10.

428 **REFERENCES**

- 429 1. Shapiro RS, Cowen LE. 2012. Thermal Control of Microbial Development and Virulence:  
430 Molecular Mechanisms of Microbial Temperature Sensing. *mBio* 3.
- 431 2. Grosso-Becera MV, Servín-González L, Soberón-Chávez G. 2015. RNA structures are  
432 involved in the thermoregulation of bacterial virulence-associated traits. *Trends Microbiol*  
433 23:509–518.
- 434 3. Almlad H, Randall TE, Liu F, Leblanc K, Groves RA, Kittichotirat W, Winsor GL, Fournier  
435 N, Au E, Groizeleau J, Rich JD, Lou Y, Granton E, Jennings LK, Singletary LA, Winstone  
436 TML, Good NM, Bumgarner RE, Hynes MF, Singh M, Stietz MS, Brinkman FSL, Kumar A,  
437 Brassinga AKC, Parsek MR, Tseng BS, Lewis IA, Yipp BG, MacCallum JL, Harrison JJ.  
438 2021. Bacterial cyclic diguanylate signaling networks sense temperature. *Nat Commun*  
439 12:1986.
- 440 4. Barbier M, Oliver A, Rao J, Hanna SL, Goldberg JB, Albertí S. 2008. Novel  
441 Phosphorylcholine-Containing Protein of *Pseudomonas aeruginosa* Chronic Infection  
442 Isolates Interacts with Airway Epithelial Cells. *J Infect Dis* 197:465–473.
- 443 5. Owings JP, Kuiper EG, Prezioso SM, Meisner J, Varga JJ, Zelinskaya N, Dammer EB,  
444 Duong DM, Seyfried NT, Albertí S, Conn GL, Goldberg JB. 2016. *Pseudomonas*  
445 *aeruginosa* EftM Is a Thermoregulated Methyltransferase. *J Biol Chem* 291:3280–3290.
- 446 6. Barbier M, Damron FH, Bielecki P, Suárez-Diez M, Puchałka J, Albertí S, Santos VM dos,  
447 Goldberg JB. 2014. From the Environment to the Host: Re-Wiring of the Transcriptome of  
448 *Pseudomonas aeruginosa* from 22°C to 37°C. *PLOS ONE* 9:e89941.


- 449 7. Wurtzel O, Yoder-Himes DR, Han K, Dandekar AA, Edelheit S, Greenberg EP, Sorek R,  
450 Lory S. 2012. The Single-Nucleotide Resolution Transcriptome of *Pseudomonas*  
451 *aeruginosa* Grown in Body Temperature. *PLOS Pathog* 8:e1002945.
- 452 8. Engel LS, Hill JM, Caballero AR, Green LC, O'Callaghan RJ. 1998. Protease IV, a unique  
453 extracellular protease and virulence factor from *Pseudomonas aeruginosa*. *J Biol Chem*  
454 273:16792–16797.
- 455 9. Traidej M, Marquart ME, Caballero AR, Thibodeaux BA, O'Callaghan RJ. 2003.  
456 Identification of the active site residues of *Pseudomonas aeruginosa* protease IV.  
457 Importance of enzyme activity in autoprocessing and activation. *J Biol Chem* 278:2549–  
458 2553.
- 459 10. Malloy JL, Veldhuizen RAW, Thibodeaux BA, O'Callaghan RJ, Wright JR. 2005.  
460 *Pseudomonas aeruginosa* protease IV degrades surfactant proteins and inhibits surfactant  
461 host defense and biophysical functions. *Am J Physiol Lung Cell Mol Physiol* 288:L409-418.
- 462 11. Guillon A, Brea D, Morello E, Tang A, Jouan Y, Ramphal R, Korkmaz B, Perez-Cruz M,  
463 Trottein F, O'Callaghan RJ, Gosset P, Si-Tahar M. 2016. *Pseudomonas aeruginosa*  
464 proteolytically alters the interleukin 22-dependent lung mucosal defense. *Virulence* 8:810–  
465 820.
- 466 12. Engel LS, Hobden JA, Moreau JM, Callegan MC, Hill JM, O'Callaghan RJ. 1997.  
467 *Pseudomonas* deficient in protease IV has significantly reduced corneal virulence. *Invest*  
468 *Ophthalmol Vis Sci* 38:1535–1542.
- 469 13. Engel LS, Hill JM, Moreau JM, Green LC, Hobden JA, O'Callaghan RJ. 1998.  
470 *Pseudomonas aeruginosa* protease IV produces corneal damage and contributes to  
471 bacterial virulence. *Invest Ophthalmol Vis Sci* 39:662–665.

- 472 14. O’Callaghan RJ, Engel LS, Hobden JA, Callegan MC, Green LC, Hill JM. 1996.  
473 Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal  
474 virulence. Invest Ophthalmol Vis Sci 37:534–543.
- 475 15. Willcox MDP. 2007. Pseudomonas aeruginosa Infection and Inflammation During Contact  
476 Lens Wear: A Review. Optom Vis Sci 84:273–278.
- 477 16. Grossman MK, Rankin DA, Maloney M, Stanton RA, Gable P, Stevens VA, Ewing T,  
478 Saunders K, Kogut S, Nazarian E, Bhaurla S, Mephors J, Mongillo J, Stonehocker S,  
479 Prignano J, Valencia N, Charles A, McNamara K, Fritsch WA, Ruelle S, Plucinski CA, Sosa  
480 LE, Ostrowsky B, Ham DC, Walters MS, for the Multistate Pseudomonas Outbreak  
481 Investigation Group. 2024. Extensively Drug-Resistant Pseudomonas aeruginosa  
482 Outbreak Associated With Artificial Tears. Clin Infect Dis ciae052.
- 483 17. Traidej M, Caballero AR, Marquart ME, Thibodeaux BA, O’Callaghan RJ. 2003. Molecular  
484 analysis of Pseudomonas aeruginosa protease IV expressed in Pseudomonas putida.  
485 Invest Ophthalmol Vis Sci 44:190–196.
- 486 18. Oh J, Li X-H, Kim S-K, Lee J-H. 2017. Post-secretional activation of Protease IV by  
487 quorum sensing in Pseudomonas aeruginosa. 1. Sci Rep 7:4416.
- 488 19. O’Callaghan R, Caballero A, Tang A, Bierdeman M. 2019. Pseudomonas aeruginosa  
489 Keratitis: Protease IV and PASP as Corneal Virulence Mediators. Microorganisms 7.
- 490 20. Wilderman PJ, Vasil AI, Johnson Z, Wilson MJ, Cunliffe HE, Lamont IL, Vasil ML. 2001.  
491 Characterization of an Endoprotease (PrpL) Encoded by a PvdS-Regulated Gene in  
492 Pseudomonas aeruginosa. Infect Immun 69:5385–5394.


- 493 21. Castang S, McManus HR, Turner KH, Dove SL. 2008. H-NS family members function  
494 coordinately in an opportunistic pathogen. *Proc Natl Acad Sci U S A* 105:18947–18952.
- 495 22. Lippa AM, Gebhardt MJ, Dove SL. 2021. H-NS-like proteins in *Pseudomonas aeruginosa*  
496 coordinately silence intragenic transcription. *Mol Microbiol* 115:1138–1151.
- 497 23. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH. 2003. Microarray Analysis of  
498 *Pseudomonas aeruginosa* Quorum-Sensing Regulons: Effects of Growth Phase and  
499 Environment. *J Bacteriol* 185:2080–2095.
- 500 24. Schuster M, Lostroh CP, Ogi T, Greenberg EP. 2003. Identification, timing, and signal  
501 specificity of *Pseudomonas aeruginosa* quorum-controlled genes: a transcriptome  
502 analysis. *J Bacteriol* 185:2066–2079.
- 503 25. Schuster M, Greenberg EP. 2007. Early activation of quorum sensing in *Pseudomonas*  
504 *aeruginosa* reveals the architecture of a complex regulon. *BMC Genomics* 8:287.
- 505 26. Pappenfort K, Bassler B. 2016. Quorum-Sensing Signal-Response Systems in Gram-  
506 Negative Bacteria. *Nat Rev Microbiol* 14:576–588.
- 507 27. Gilbert KB, Kim TH, Gupta R, Greenberg EP, Schuster M. 2009. Global position analysis of  
508 the *Pseudomonas aeruginosa* quorum-sensing transcription factor LasR. *Mol Microbiol*  
509 73:1072–1085.
- 510 28. Andersen JB, Sternberg C, Poulsen LK, Bjørn SP, Givskov M, Molin S. 1998. New  
511 Unstable Variants of Green Fluorescent Protein for Studies of Transient Gene Expression  
512 in Bacteria. *Appl Environ Microbiol* 64:2240–2246.

- 513 29. Rybtke MT, Borlee BR, Murakami K, Irie Y, Hentzer M, Nielsen TE, Givskov M, Parsek MR,  
514 Tolker-Nielsen T. 2012. Fluorescence-Based Reporter for Gauging Cyclic Di-GMP Levels  
515 in *Pseudomonas aeruginosa*. *Appl Environ Microbiol* 78:5060–5069.
- 516 30. Coppens L, Lavigne R. 2020. SAPPHIRE: a neural network based classifier for  $\sigma$ 70  
517 promoter prediction in *Pseudomonas*. *BMC Bioinformatics* 21:415.
- 518 31. Farrow JM, Pesci EC. 2017. Distal and proximal promoters co-regulate pqsR expression in  
519 *Pseudomonas aeruginosa*. *Mol Microbiol* 104:78–91.
- 520 32. Farrow JM, Hudson LL, Wells G, Coleman JP, Pesci EC. 2015. CysB Negatively Affects  
521 the Transcription of pqsR and *Pseudomonas* Quinolone Signal Production in  
522 *Pseudomonas aeruginosa*. *J Bacteriol* 197:1988–2002.
- 523 33. Prasad ASB, Shruptha P, Prabhu V, Srujan C, Nayak UY, Anuradha CKR, Ramachandra L,  
524 Keerthana P, Joshi MB, Murali TS, Satyamoorthy K. 2020. *Pseudomonas aeruginosa*  
525 virulence proteins pseudolysin and protease IV impede cutaneous wound healing. *Lab*  
526 *Investig J Tech Methods Pathol* 100:1532–1550.
- 527 34. Kim T-H, Li X-H, Lee J-H. Alleviation of *Pseudomonas aeruginosa* Infection by Propeptide-  
528 Mediated Inhibition of Protease IV. *Microbiol Spectr* 9:e00782-21.
- 529 35. Caballero AR, Moreau JM, Engel LS, Marquart ME, Hill JM, O’Callaghan RJ. 2001.  
530 *Pseudomonas aeruginosa* protease IV enzyme assays and comparison to other  
531 *Pseudomonas* proteases. *Anal Biochem* 290:330–337.
- 532 36. Grosso-Becerra MV, Croda-García G, Merino E, Servín-González L, Mojica-Espinosa R,  
533 Soberón-Chávez G. 2014. Regulation of *Pseudomonas aeruginosa* virulence factors by  
534 two novel RNA thermometers. *Proc Natl Acad Sci* 111:15562–15567.

- 535 37. Whiteley M, Lee KM, Greenberg EP. 1999. Identification of genes controlled by quorum  
536 sensing in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 96:13904–13909.
- 537 38. Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO. 2009. Enzymatic  
538 assembly of DNA molecules up to several hundred kilobases. *Nat Methods* 6:343–345.
- 539 39. Hmelo LR, Borlee BR, Almblad H, Love ME, Randall TE, Tseng BS, Lin C, Irie Y, Storek  
540 KM, Yang JJ, Siehnel RJ, Howell PL, Singh PK, Tolker-Nielsen T, Parsek MR, Schweizer  
541 HP, Harrison JJ. 2015. Precision-engineering the *Pseudomonas aeruginosa* genome with  
542 two-step allelic exchange. *Nat Protoc* 10:1820–1841.
- 543 40. Chen W, Zhang Y, Zhang Y, Pi Y, Gu T, Song L, Wang Y, Ji Q. 2018. CRISPR/Cas9-based  
544 Genome Editing in *Pseudomonas aeruginosa* and Cytidine Deaminase-Mediated Base  
545 Editing in *Pseudomonas* Species. *iScience* 6:222–231.
- 546 41. Engler C, Gruetzner R, Kandzia R, Marillonnet S. 2009. Golden Gate Shuffling: A One-Pot  
547 DNA Shuffling Method Based on Type II restriction Enzymes. *PLOS ONE* 4:e5553.
- 548 42. Choi K-H, Schweizer HP. 2006. mini-Tn 7 insertion in bacteria with single att Tn 7 sites:  
549 example *Pseudomonas aeruginosa*. *Nat Protoc* 1:153–161.
- 550




**Figure 1. Temperature regulation of *piv* depends on growth phase.** A) PAO1 was grown at 25°C, 30°C, 37°C, and 42°C. RNA was extracted from an equal number of cells first at exponential phase and then from the same cultures at early stationary phase, at points during bacterial growth indicated by arrows on the y-axis. The average growth of three biological replicates is shown with error bars representing standard deviation. B) Expression of *piv* at each temperature was calculated relative to 37°C using *omlA* as a temperature insensitive, internal control gene. RT-qPCR was conducted in technical triplicate and the mean of three biological replicates is shown with error bars representing standard deviation. Statistical significance was determined by two-way ANOVA with Dunnett's multiple comparisons: \*  $p < 0.0332$ , \*\*  $p < 0.0021$ , \*\*\*  $p < 0.0002$ , \*\*\*\*  $p < 0.0001$ , ns – not significant. Values between the dotted lines were not considered biologically significant.




**Figure 2. Temperature regulation of *piv* expression is reflected by levels of PIV protein.** A) Cell lysates of PAO1 PIV VSV-G grown to early stationary phase at 25°C, 30°C, 37°C, and 42°C were probed with antibodies against the VSV-G tag ( $\alpha$ VSV-G) and the RNA polymerase  $\alpha$  subunit ( $\alpha$ RpoA). A representative image of three biological replicates is shown. B) The amount of mature PIV VSV-G protein at each temperature was determined relative to the amount of RpoA using ImageJ. The mean of three biological replicates is shown with standard deviation. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparisons: \*  $p < 0.0332$ , \*\*  $p < 0.0021$ , \*\*\*  $p < 0.0002$ , \*\*\*\*  $p < 0.0001$ , ns – not significant.


**A**




**B**




**C**




**D**



**Figure 3. Transcriptional regulators of *piv* are not thermoregulated.** A) PAO1 was grown at 25°C and 37°C and RNA extracted at exponential and stationary phases as previously described. Expression of genes was determined by RT-qPCR using *omlA* as an internal control gene and calculated for 25°C relative to 37°C. RT-qPCR was conducted in technical triplicate. The mean of three biological replicates analyzed is shown with error bars representing standard deviation. Values between the dotted lines were not considered biologically significant. B,C,D) Western blots (left) and subsequent quantification (right) of indicated transcription factors in cells grown at 25°C and 37°C to stationary phase. B) PAO1 was probed with  $\alpha$ LasR antibodies. C) PAO1 MvaT VSV-G was probed with  $\alpha$ VSV-G antibodies. D) PAO1 MvaU VSV-G was probed with  $\alpha$ VSV-G antibodies. All samples were probed with  $\alpha$ RpoA as a loading control. Biological triplicates for each protein are shown. For densitometry analysis, the amount of LasR (B), MvaT VSV-G (C), and MvaU VSV-G (D) protein was determined relative to the amount of RpoA in the same sample using ImageJ. The mean of three biological replicates is shown with standard deviation. Statistical significance was determined by two-tailed t test, ns – not significant.




**Figure 4. Temperature alters activity of the *piv* promoter through transcriptional regulator LasR, but not MvaT/MvaU.** The indicated strains carrying the P<sub>piv</sub>-gfp(ASV) transcriptional reporter (pRD91) were grown at 25°C and 37°C. An equal number of cells were sampled for fluorescence (RFU) measurements (excitation 485 nm, emission 515 nm) first at exponential phase (A) and then at early stationary phase (B). The dotted line indicates background fluorescence of PAO1 carrying a no-promoter *gfp*(ASV) reporter plasmid (pRD87). Three biological replicates were performed, with RFU measurements conducted in technical triplicate per each. The mean of three biological replicates is shown with error bars representing standard deviation. Statistical significance was determined by two-way ANOVA with Šídák multiple comparisons: \*  $p < 0.0332$ , \*\*  $p < 0.0021$ , \*\*\*  $p < 0.0002$ , \*\*\*\*  $p < 0.0001$ , ns – not significant. Statistical comparisons shown are for a given strain grown at 25°C versus 37°C.



**Figure 5. Mutations to a putative *las box* in the *piv* promoter region alter promoter activity.**  
A) Sequence of the 200 nucleotides upstream of the *piv* start codon that are sufficient for temperature and growth phase regulation. Putative  $\sigma^{70} -35$  and  $-10$  elements identified with

SAPPHIRE (30) are underlined. Nearby transcription start sites (TSSs) were identified by 5' RACE are highlighted. A DNA motif with similarity to canonical *las* boxes (27) was identified upstream of transcription initiation regions and is boxed. B) Mutations made to the *las* box within the *piv* promoter of the  $P_{piv}$ -*gfp*(ASV) transcriptional reporter plasmid (pRD91). Mutations are predicted to disrupt (in pink) or improve (in green) LasR binding based on comparison to the consensus sequence. C) PAO1 carrying *las* box mutants of the  $P_{piv}$ -*gfp*(ASV) transcriptional reporter shown in B) were grown at 25°C and 37°C and fluorescence measurements taken at exponential (left) and stationary (right) phases as previously described. The mean of three biological replicates analyzed with standard deviation is shown. Statistical significance was determined two-way ANOVA with Šídák multiple comparisons: \*  $p < 0.0332$ , \*\*  $p < 0.0021$ , \*\*\*  $p < 0.0002$ , \*\*\*\*  $p < 0.0001$ .



**Figure 6. The proposed model for the transcriptional thermoregulation of *piv* by the quorum sensing regulator LasR.** At 25°C (blue thermometer), LasR drives high expression of *piv* at stationary phase by directly interacting with the *piv* promoter while MvaT/MvaU do not repress expression. At 37°C (red thermometer), LasR no longer directly regulates *piv*, which allows MvaT/MvaU to repress *piv* expression.